DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2017
Market Outlook Squamous cell carcinoma of the head and neck ( SCCHN ) is an anatomically and biologically heterogeneous disease, which has historically proven a complex challenge for drug…
Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 2 | 2017
With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…
Hospital-Treated Gram-Negative Infections | Current Treatment: Physician Insights | US | 2017
Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…
Methicillin-Resistant Staphyloccocus Aureus Infections (MRSA) | Outpatient Parenteral Antibiotic Therapy (OPAT) | Current Treatment | Physician Insights | US | 2017
Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…
Emerging Therapies Ocrevus Relapsing Forms of Multiple Sclerosis – Wave 2 (US) – 2017
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers…
